Last quarter (Q2 2023), Evgen Pharma's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Evgen Pharma's net income was £―. See Evgen Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	-	£ 442.00K	-	£ 194.00K	£ 0.00	£ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	£ 442.00K	-	-	-	-
Operating Expense	-	£ 5.51M	£ 3.19M	£ 3.40M	£ 3.15M	£ 3.12M
Operating Income	-	£ -5.07M	-	£ -3.20M	£ -3.15M	£ -3.12M
Net Non Operating Interest Income Expense	-	£ 98.00K	£ 24.00K	-	-	-
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	£ -5.01M	£ -3.17M	£ -3.21M	£ -3.17M	£ -3.12M
Tax Provision	-	£ -963.00K	£ -439.00K	£ -539.00K	£ -451.00K	£ -496.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -4.04M	-	£ -2.67M	£ -2.71M	£ -2.62M
Basic EPS	-	£ -0.01	£ -0.99	£ -0.02	£ -0.02	£ -0.03
Diluted EPS	-	£ -0.01	£ -0.99	£ -0.02	£ -0.02	£ -0.03
Basic Average Shares	-	£ 274.89M	£ 274.89M	£ 149.20M	£ 131.23M	£ 97.28M
Diluted Average Shares	-	£ 274.89M	£ 274.89M	£ 149.20M	£ 131.23M	£ 97.28M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	£ 30.00K	£ 32.00K
Total Expenses	-	£ 5.51M	-	£ -3.40M	£ 3.15M	£ 3.12M
Net Income From Continuing And Discontinued Operation	-	£ -4.04M	£ -2.73M	£ -2.67M	£ -2.71M	£ -2.62M
Normalized Income	-	£ -5.97M	£ -3.61M	£ -3.75M	£ -2.71M	£ -2.62M
Interest Expense	-	-	-	-	-	-
EBIT	-	£ -5.01M	£ -3.17M	£ -3.21M	£ -3.15M	£ -3.12M
EBITDA	-	£ -4.99M	£ -3.15M	£ -3.21M	£ -3.13M	£ -3.10M

Currency in GBP

Evgen Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing